Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PTX

Pernix Therapeutics (PTX) Stock Price, News & Analysis

Pernix Therapeutics logo

About Pernix Therapeutics Stock (NASDAQ:PTX)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.03
$0.21
52-Week Range
N/A
Volume
16,105 shs
Average Volume
3.04 million shs
Market Capitalization
$419 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs primarily for the United States market. It targets underserved therapeutic areas, such as central nervous system (CNS), including pain, neurology, and psychiatry. The company's products comprise Zohydro ER with BeadTek, an opioid agonist indicated for the management of pain; Silenor, a non-narcotic, non-scheduled, and non-addictive prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance; and Treximet, a fixed dose combination product indicated for the treatment of acute migraine. Pernix Therapeutics Holdings, Inc. markets and sells its non-core products, including generics through its wholly owned subsidiaries; and markets its non-promoted products through distributors and trade partners. It serves drug wholesalers, specialty pharmacies, retail drug stores, mass merchandisers, and grocery store pharmacies. Pernix Therapeutics Holdings, Inc. was founded in 1996 and is headquartered in Morristown, New Jersey.

Receive PTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pernix Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PTX Stock News Headlines

PANXD PTX Metals Inc.
Bicycle Therapeutics PLC ADR BCYC
New Rule Hits in July — The Smart Money Already Moved
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
Prescient Therapeutics Ltd
Pernix Therapeutics Holdings Inc (PTX)
See More Headlines

PTX Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Pernix Therapeutics investors own include PIMCO High Income Fund (PHK), Synergy Pharmaceuticals (SGYP), Investors Bancorp (ISBC), Novavax (NVAX), Gevo (GEVO), Amira Nature Foods (ANFI) and Argos Therapeutics (ARGSQ).

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:PTX
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$77.14 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$146.07 million
Price / Cash Flow
N/A
Book Value
($14.77) per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$419 thousand
Optionable
Optionable
Beta
1.20
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:PTX) was last updated on 6/21/2025 by MarketBeat.com Staff
From Our Partners